Abstract 1586P
Background
According to GLOBOCAN's 2024 report breast cancer (BC) is the second leading cause of cancer, posing a significant health challenge in both developed (DE) and developing countries (DC) (Bray F., 2024). Among women, BC is the most commonly diagnosed cancer and the leading cause of cancer deaths, with an estimation of 2.3 million new cases and 666,000 deaths in 2022.
Methods
We performed a critical review of the disparities in BC between DE and DC countries using data from the GLOBOCAN and the North American Association of Central Cancer Registries databases, alongside pertinent literature.
Results
DE countries show substantially higher incidence rates (54.1 vs 30.8 per 100,000), peaking in France, Australia/New Zealand, North America and Northern Europe. Conversely, mortality rates are significantly higher in DC countries (15.3 vs 11.3 per 100,000) (Bray F., 2024). Compared with the risk factors for age-standardized death rate (ASDR) in 1990, smoking and alcohol consumption decreased. In contrast, high plasma glucose and body mass index were ranked as significant contributors to increased ASDR in 2019 (Lv L., 2023). In DE countries, BC incidence increased until 2000, then stabilized and rised again since 2005 (Breen N., 2011). Meanwhile, the mortality rate declined in recent years (Bray F., 2024; Cronin KA., 2022). In contrast, DC countries are witnessing rapid increases in both incidence and mortality rates, driven by socioeconomic transitions, urbanization, obesity, changes in female reproductive patterns and challenges of healthcare systems (Lv L., 2023; Ginsburg O., 2017). Early detection and treatment improve survival rates, but DC countries often face late-stage diagnosis due to limited screening and cancer care (Brand NR., 2019). The WHO’s 2021 Global Initiative aims to lower mortality by 2.5% yearly through enhanced health promotion, early detection and comprehensive management of the disease (WHO., 2023).
Conclusions
BC remains a global challenge with pronounced disparities between DE and DC countries in incidence, mortality and survival. These differences highlight the need for a coordinated global response that addresses risk factors, early detection and ensures access to treatment, regardless of the geographical location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10